Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zosuquidar + Gemtuzumab Ozogamicin in CD33+ AML
NCT00233909Phase 2Completed
- Sponsor
- Kanisa Pharmaceuticals
- Start
- Oct 2005
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of zosuquidar in acute myeloid leukemia (AML), sponsored by Kanisa Pharmaceuticals. Started Oct 2005; status: completed.
02
Drugs
zosuquidar
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00233909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233909.